Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

Next Previous
X
Search
Trial Profile

A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pirtobrutinib (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
  • Indications B-cell leukaemia; B-cell lymphoma; B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hairy cell leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man; Proof of concept; Registrational; Therapeutic Use
  • Acronyms BRUIN
  • Sponsors Loxo Oncology

    • Most Recent Events

    • 28 Jun 2024 According to a Nippon Shinyaku Co Ltd media release, based on the efficacy and safety results of study BRUIN-18001, company has received marketing authorization in Japan for the antineoplastic agent (Jaypirca) 50 mg and 100 mg tablets for the treatment of patients with relapsed or refractory mantle cell lymphoma who are resistant or intolerant to other BTK inhibitors.
    • 24 Jun 2024 Results published in a Nippon Shinyaku Co Ltd media release
    • 25 Mar 2024 Planned End Date changed from 1 Apr 2024 to 1 Jan 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top